Combined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer
Combination Treatment of Nivolumab, Ipilimumab, Intratumoral CMP-001 and Radiosurgery for Liver Metastases in Colorectal Carcinoma
Sponsor: Bristol-Myers Squibb
This PHASE1 trial investigates Colorectal Neoplasms Malignant and Liver Metastases and is currently completed. Bristol-Myers Squibb leads this study, which shows 9 recorded versions since 2018 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
May 2023 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Jun 2022 — May 2023 [monthly]
Active Not Recruiting PHASE1
Status: Unknown Status → Active Not Recruiting
-
Oct 2021 — Jun 2022 [monthly]
Unknown Status PHASE1
Status: Recruiting → Unknown Status
▶ Show 4 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE1
-
Feb 2019 — Jan 2021 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Feb 2019 [monthly]
Not Yet Recruiting PHASE1
-
May 2018 — Jun 2018 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
- Checkmate Pharmaceuticals
- Sheba Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .